Davidson 2001b.

Methods	DESIGN Description: random‐assignment, placebo‐controlled, relapse prevention study for participants undergoing acute and continuation treatment in Brady 2000 and Davidson 2001a BLINDING Participants: Unclear Assessors: Unclear Administrators: Unclear ALLOCATION CONCEALMENT Method: Unclear RANDOMISATION Method: unclear
Participants	SAMPLE 96 DSM‐III‐R PTSD, mean age=43.4 years, SD=10.3, 30% male SCREENING Responders (CGI ≤ 2, ≥30% improvement on total severity score for CAPS) in last two sessions of 28 week continuation treatment with sertraline
Interventions	Sertraline 50‐200 mg/d (avg 137 mg/day) vs. placebo (avg 145 mg/day) x 28 weeks
Outcomes	Primary outcomes: Rates and times to event for 1) relapse, 2) relapse or discontinuation because of clinical deterioration (self‐ rated), and 3) acute exacerbation of PTSD. Secondary outcomes: CAPS, HAM‐D, QLES Data estimation: Not applicable for primary outcomes (Kaplan Meier survival analysis)
Notes	INDUSTRY SUPPORT Industry funded: Yes (as reported in acute and continuation phase studies) Medication provided by industry: No (as reported in acute and continuation phase studies) Any of the authors work for industry: Yes